UK markets open in 59 minutes

Veracyte, Inc. (VCYT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
17.31+0.73 (+4.40%)
At close: 04:00PM EDT
17.00 -0.31 (-1.79%)
After hours: 07:58PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • N
    Nathan
    What to love about VCYT:
    1. Genomic healthcare: Im not a doctor nor a scientist, but it's pretty safe to assume genomic research, diagnoses, and treatment will be a huge part of healthcare in 10-20 years. It seems like we have barely scratched the surface with this field. Could degenerative diseases like Alzheimers, Parkinson's, and dementia be cured by digging into DNA and genetics of an individual? Could cancers be diagnosed much earlier so treatment is more successful? It's exciting.

    2. Bonnie Anderson: Bonnie Anderson, the CEO, co-founded Veracyte a little over a decade ago and has been with the company ever since. I love this fact, seeing as Bonnie not only knows every crack and crevice of the industry by now, but she is also very passionate about her work and the company she founded, or she would have moved on years ago. Co-founders seem to always pack a little extra "punch" in a company....especially if they are in leadership roles.

    3. Johnson & Johnson: JNJ and VCYT are collaborating in a lung cancer project, which aims to diagnose lung cancer early with a nasal swab. The things they are doing are revolutionary, but the fact that a behemoth company like JNJ puts trust in VCYT speaks a million words. The collab seems to give VCYT a safety net as well that other genomic companies do not have.

    I didn't think i'd have another opportunity to buy shares at less than $30 after that great earnings report, but here we are. Thank you sir, may I have another?
  • L
    Live forever
    Having worked in Medical Device selling implants to hospitals and Physicians, Diagnostics is where it is at today. Not only the patient benefit of having AI review your results but if Insurance companies can mandate these tests and use them to prevent Doctors from doing costly procedures, they will support them 100%. This company produces products that are Better, Faster and Cheaper than alternatives. Strong Long....

    Love the Acquisition to open new doors and fill out the bag and diversify growth paths.
  • s
    steve
    $200M in the bank very little debt and will be profitable within 6 months. JnJ partnership, flush pipeline. Small float, market cap at only 1B. ARK funds top 10 holding. What more can I say, this is my favorite biotech!
  • m
    mike
    Just wanted to make a post since its been a month since the last one. Anyone with any valued points to share on the future stock price of this company? 42 by September 30!
  • s
    steve
    Veracyte estimates that the market opportunity for its nasal swab test, when used to assess lung cancer risk in patients with lung nodules identified by imaging is approximately $1.9 billion in the United States and $3.9 billion for both the U.S. and European Union. Veracyte also plans to explore opportunities to deploy its “field of injury” technology at other points along the lung cancer care continuum. The company believes the overall global lung cancer diagnostic market is approximately $30 billion.
  • N
    Neilio
    Great Quarter. This is going to start to move up nicely.
  • s
    steve
    The 1st of many new partnerships. This is my favorite stock in Biotech.
  • u
    universe
    VCYT love this company..along with the upside reasons mentioned in the excellent posts below - Nanostring acquisition is going to further proper their innovation and revenues. The management team, both technology and commercialization is A+. I agree this is a stock for the long term!
  • J
    JeffreyT
    PT raised to $50. That was fast.
  • P
    Phil
    Just added some here. A little oversold but I’m holding long term so it doesn’t matter what it does within 2 or 3 days.
  • J
    JeffreyT
    Company out with a bunch of positive data this week. Clearly a player in cancer genomics.
  • J
    JeffreyT
    First genomic test in prostate cancer to get reimbursement approval? I think that is substantial.
  • N
    Nathan
    I've always operated by this theory: NEVER sell Biotechs. They can literally find the cure for cancer overnight and jump 400%. I am not interested in being the guy that sells for $55 and misses out on $500 if something like that happens.

    This is taking up a much larger space in my portfolio than i'd like. But, i'm nervous they find the cure for lung cancer overnight if I take some profits. What to do, what to do?
  • m
    mike
    Can anyone please tell me why this stock goes down three or four dollars everytime they have great earnings
  • m
    mike
    Anyone comment on this stock good or bad?
  • O
    Outperform
    Does anyone know how much of VCYT's revenue is thyroid testing?
  • L
    Live forever
    Was long VCYT but was triggered out by Stop Loss in the 70s. Seems like a bargain now compared to 52w High but Mkt Cap is still HUGE compared to annual revenues. Think PPS is pumped by ARK funds buying in.

    Did some research of other competitors and found FLGT. Same type of company except were profitable before Covid, then got CDC contract (which will not last but helped them put $420M in Cash+AR-AP on their B/S). Total gift to fund ongoing ops without debt or dilutive equity fundraising.

    Stock is down 57% from 52w high as the pumpers have exited and the fear of the Covid revenues (which are substantial) going away. Thought I would share w others on the board in the event someone wanted to diversify in this space.

    All these companies are banking on the future with the same problem - operational burn rate is not currently supported by Gross Profit. It boils down to how much cash they have on the B/S before they have to raise more cash (and how will that effect future profits or investors).

    Good luck to all....
  • I
    InverseCramer
    Great news today. Conference call at 5:30 PM
  • N
    Nathan
    Top-line beat, bottom line miss. Major increase in "loss from operations" was the main reason for the bottom line miss. Anyone know if this was just losses from COVID layoffs/furloughs or if something else went very wrong?

    The balance sheet still looks phenomenal. Nothing changes on the long-term outlook in my opinion.